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Protein formulationa b s t r a c t
A Raman spectrometer and dynamic light scattering system were combined in a single platform (Raman–
DLS) to provide concomitant higher order structural and hydrodynamic size data for therapeutic proteins
at high concentration. As model therapeutic proteins, we studied human serum albumin (HSA) and intra-
venous immunoglobulin (IVIG). HSA concentration and temperature interval during heating did not affect
the onset temperatures for conformation perturbation or aggregation. The impact of pH on thermal sta-
bility of HSA was tested at pHs 3, 5, and 8. Stability was the greatest at pH 8, but distinct unfolding and
aggregation behaviors were observed at the different pHs. HSA structural transitions and aggregation
kinetics were also studied in real time during isothermal incubations at pH 7. In a forced oxidation study,
it was found that hydrogen peroxide (H2O2) treatment reduced the thermal stability of HSA. Finally, the
structure and thermal stability of IVIG were studied, and a comprehensive characterization of heating-
induced structural perturbations and aggregation was obtained. In conclusion, by providing comprehen-
sive data on protein tertiary and secondary structures and hydrodynamic size during real-time heating or
isothermal incubation experiments, the Raman–DLS system offers unique physical insights into the prop-
erties of high-concentration protein samples.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).There are several points during the development history of a
therapeutic protein product where there is a need to rapidly assess
protein structure, aggregation, and thermal stability. For example,
during early development of a therapeutic monoclonal antibody
(mAb)1, relative physical stability (e.g., during heating) and aggrega-
tion propensity are often compared among several candidate vari-
ants of the antibody [1]. This early testing allows for choice of the
variant with the most favorable physical pharmaceutical properties.
Similar testing can be performed with the chosen product candidate
during pre-formulation studies and formulation development in
which the effects of solution conditions such as pH and different
excipients on protein unfolding/aggregation are determined [2,3].
These studies are also often conducted under so-called ‘‘accelerated
degradation’’ conditions of heating or exposure to other stresses
such as forced oxidation. And even after commercial launch of atherapeutic protein, there may be a need to compare its thermal sta-
bility and aggregation before and after a manufacturing change [4–
6]. Such studies are a vital part of the characterization that is
required to provide assurance that the product made by the new
manufacturing approach is comparable to the protein made by the
original process.
Traditionally for such studies, multiple techniques have been
used separately to characterize protein conformation, aggregation,
and thermal stability, with the results from different instruments
being combined to provide an overall assessment of the protein’s
physicochemical properties [7]. To characterize size and aggrega-
tion, size exclusion chromatography (SEC) is widely and routinely
used to quantify the amount of monomer, dimer, trimer, and
higher order oligomers [8,9]. Other techniques such as ﬁeld ﬂow
fractionation (FFF) and analytical ultracentrifugation (AUC) are
used for orthogonal conﬁrmation of SEC results [10–12]. Dynamic
light scattering (DLS), static light scattering (SLS), and turbidity
measurements are also used to monitor protein aggregation. For
studies of protein structure combined with determination of rela-
tive stability (e.g., during heating), optical spectroscopic
techniques with varied structural resolution and sensitivity are
commonly used, including intrinsic/extrinsic ﬂuorescence, ultravi-
Fig.1. Diagram of the instrument with Raman spectroscopy combined with DLS.
APD, avalanche photodiode.
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and infrared (IR) [10,12].
The capacity to perform different measurements in parallel on
the same sample is particularly valuable. Often material for studies
is limited, especially during the early comparisons between vari-
ants of a given mAb product. Obtaining more than one data type
from a given sample (e.g., UV absorbance spectra and turbidity
measurements, ﬂuorescent spectra and SLS measurements) helps
to conserve precious protein. In addition, making simultaneous
measurements on a sample ensures that critical solution and pro-
cessing conditions are identical and that variations in sample han-
dling and instrument operations are minimized.
This consistency is particularly important for real-time studies
of protein structure and/or aggregation during heating. Real-time
heating studies are useful for relatively rapid characterization of
protein stability, but in most cases the protein will aggregate dur-
ing heating. Because this is an irreversible process, many different
factors—such as protein concentration, heating rate, and dwell
time at a given temperature for data acquisition—can affect the
thermal transition temperatures and, hence, the parameters used
to assess relative protein stability. Therefore, often thermal transi-
tion temperatures for the same protein obtained on two different
instruments will not agree unless extreme care is taken to match
all relevant conditions. Sometimes it is not physically possible to
obtain the requisite matches between instruments, and then the
thermal transition temperatures for different processes, such as
protein secondary structural change due to unfolding and protein
assembly due to aggregation, cannot be compared rigorously.
The high-concentration formulations used for many modern
mAb therapeutics and some older products such as human serum
albumin (HSA) and intravenous immunoglobulin (IVIG) make ana-
lytical assessment more complicated, even when a single method
is used. At the tens of milligrams concentrations found in many
of these formulations, certain methods such as ﬂuorescence and
far-UV CD spectroscopies might not be viable without sample dilu-
tion. Dilution should be avoided in studying protein structure and
aggregation because a protein’s physical properties and behavior in
a dilute solution often do not match those occurring at the actual
protein concentration in the product.
In the current study, we addressed these different analytical
challenges by using combined parallel measurements of the same
sample with Raman spectroscopy and DLS to study the structure,
thermal stability, and aggregation of model therapeutic proteins
(HSA and IVIG) at high concentrations. DLS, based on the time-
dependent correlation of light intensity ﬂuctuation due to Brown-
ian motion of particles, is robust for qualitatively analyzing particle
size and sample polydispersity for particle diameters from several
nanometers (nm) to a few micrometers (lm). The 173 backscat-
tering detector minimizes interference from multiple scatterings
and enables the collection of size distribution data of high-concen-
tration protein samples [10]. Raman spectra provide secondary and
tertiary structural information through analysis of peak positions
and ratios of spectral features that characterize amide I, amide
III, and other backbone vibrations (used to characterize the second-
ary structure both qualitatively and quantitatively) as well as
peaks for vibrations of aromatic side chains such as tyrosine
(Tyr) and tryptophan (Trp) (used to monitor protein tertiary struc-
ture) [13–17]. Compared with IR spectroscopy, Raman spectros-
copy requires minimal sample preparation and is less sensitive to
water vibrations that interfere with the amide I band, making it
less difﬁcult to subtract this water contribution [18]. Raman spec-
troscopy is also ideally suited to studying proteins at high concen-
tration [19].
By combining the DLS and Raman spectroscopy systems, we
were able to characterize the size distribution and conformation
at the same time for the same protein sample. This approachavoids variation issues arising from sample to sample as well as
instrumental and experimental conditions. In addition, by acquir-
ing Raman spectra and light scattering data during real-time heat-
ing studies and during isothermal incubations at various
temperatures, we were able to directly compare the effects of tem-
perature or time of incubation on protein secondary and tertiary
structure as well as aggregation.
In our experiments, thermal stability of HSA at pH 7 was ﬁrst
studied to evaluate instrument capability and performance, with
varied protein concentrations and heating intervals. Then, the
effects of pH (pHs 3, 5, and 8) on HSA conformation, thermal stabil-
ity, and aggregation were characterized. In addition, during iso-
thermal incubation experiments, HSA aggregation and structural
perturbation kinetics were studied at pH 7. As an example of the
effects of chemical degradation on protein structure and thermal
stability, HSA was oxidized by exposure to hydrogen peroxide
(H2O2) and the effects on structure, aggregation, and thermal sta-
bility were compared with undamaged HSA during real-time heat-
ing experiments. Finally, we studied high-concentration
formulations of IVIG during real-time heating experiments.
Together, these experiments provide insights into the uniquely
valuable data that can be obtained with combined study of protein
structure, aggregation, and thermal stability with concomitant
Raman spectroscopy and DLS.Materials and methods
Materials
HSA (Albuminar-5, CSL Behring) and IVIG (Gammagard Liquid,
Baxter HealthCare) were purchased from the University of Colo-
rado at Boulder’s Wardenburg Pharmacy. All other chemicals were
purchased from Fisher Scientiﬁc (Hampton, NH, USA) and were of
reagent grade or higher quality.Instrument conﬁguration, experimental methods, and data analysis
For the Raman–DLS studies, a Zetasizer Nano ZS (Malvern
Instruments, Malvern, UK) was combined with a Kaiser Raman
RxN1 spectrometer (Kaiser Optical Systems, Ann Arbor, MI, USA).
The instrument is a prototype system developed by the Malvern
Bioscience Development Initiative (Columbia, MD, USA). A 785-
nm laser with an approximately 280-mW laser power source was
used for Raman spectroscopy. DLS data were collected at 632 nm
with a 173 backscattering detector that minimizes interference
from multiple scatterings and enables the collection of size distri-
bution data of high-concentration protein samples [10]. As shown
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lection to be switched between Raman spectroscopy and DLS. In
a typical experiment, an approximately 110-ll sample was placed
into a 3  3-mm quartz cuvette, which was then loaded into a Pel-
tier temperature-controlled sample compartment. To avoid poten-
tial problems due to sample evaporation, the sample cuvette was
tightly sealed with a Teﬂon stopper. Unless otherwise noted,
Raman spectra were collected with 12 co-additions of a 10-s expo-
sure (see Ref. [20]).
For experiments studying the effects of heating, data were
acquired from 20 to 90 C at 1 C intervals unless otherwise noted.
At each data acquisition temperature, Raman and DLS data were
acquired sequentially. Then, the temperature was increased at
approximately 6 C/min to the next data acquisition temperature.
The sample was allowed to equilibrate brieﬂy before the data set
was acquired and saved, a process that required approximately
4 min. This process was repeated until the experimental tempera-
ture range was covered. An automated routine in the software
from Malvern was used for the setup and running of the heating
experiments; thus, during these runs, operator input and monitor-
ing were not required.
To obtain background Raman spectra for the corresponding buf-
fer without protein, only Raman spectra were acquired during the
same temperature ramping and data acquisition protocol. The buf-
fer spectrum at each temperature was subtracted from the spec-
trum for the protein sample at the same temperature.
Raman spectral data analysis and determination of thermal
transition temperatures were performed with a prototype software
package provided by the Malvern Biosciences Development Initia-
tive. The Raman spectra midpoint temperature (Tm) and onset tem-




 þ C; ð1Þ
where y is the ﬁtted parameter, such as peak center of amide I or
contents of a-helix/b-sheet, x is the temperature, and A, B, and C
are constants. To obtain the Tonset values, the second derivative of
the ﬁt was used to ﬁnd the point of maximum curvature on the ris-
ing edge of the transition.
For DLS results obtained during heating experiments, the corre-
lation function data acquired at each temperature were examined.
It was observed that there were high-quality ﬁts with relatively
low error until sample temperatures well exceeded the onset tem-
perature for an increase in the z-averaged size. For some of these
data sets, size distributions were determined and are presented
in Results and Discussion. At higher temperatures, the ﬁts were
poor because the protein solutions had become gelled and/or
grossly precipitated, as assessed by visual observation.
The aggregation onset temperature (Tagg) during each heating
experiment was determined as the temperature where the z-aver-
aged size exceeded the base value by more than 25%. The base
value was calculated as the mean value of the hydrodynamic size
at the ﬁve initial data points.
In the initial thermal stability study of HSA, the errors for ther-
mal transition values were the results from ﬁtting errors to the
data sets for a single sample. For all of the other experiments, Tm,
Tonset, and Tagg errors were for the standard deviations from the
means of values obtained for three or more independent samples
(nP 3).
Preparation of therapeutic protein samples
HSA was dialyzed in Slide-A-Lyzer Dialysis Cassettes with a 10-
kDa molecular weight (MW) cutoff (Pierce, Rockford, IL, USA)
against 20 mM sodium phosphate–citrate buffer at 4 C, with threechanges of the external solution, the volume of which exceeded
sample volume by 1000-fold. Unless otherwise noted, pH 7 buffer
(20 mM sodium phosphate–citrate) was used with 150 mM NaCl.
Protein concentration was determined by UV absorbance at
280 nm using an extinction coefﬁcient of 0.53 cm1 ml mg1 [21].
IVIG was used without dialysis in the commercial formulation
(250 mM glycine buffer, pH 5). The protein concentration was
determined by UV absorbance at 280 nm using an extinction coef-
ﬁcient of 1.357 cm1 ml mg1 [22,23].
Initial thermal stability study of HSA
A dialyzed HSA sample at pH 7 was diluted to a protein concen-
tration of 39 mg/ml. Then, Raman spectra and DLS data were col-
lected during heating from 20 to 90 C with a data acquisition
interval of 1 C.
Effects of protein concentration and data acquisition interval on HSA
thermal stability
To study effects of protein concentration, a dialyzed HSA sample
at pH 7 was diluted to 10, 15, 20, and 39 mg/ml. Then, Raman spec-
tra and DLS data were collected during heating of samples at each
protein concentration. A data acquisition interval of 1 C was used.
In a separate study, the effects of data acquisition interval were
investigated. HSA (41 mg/ml) was heated from 20 to 90 C with
data acquisition intervals of 0.5, 1, 2, and 5 C.
Isothermal incubation of HSA
HSA (31 mg/ml) at pH 7 was incubated at 60, 63, and 65 C. Data
were collected from time 0 to approximately 200 min at time
intervals of approximately 4 min.
Effects of pH on HSA structure and thermal stability
HSA was dialyzed at 4 C against 20 mM sodium phosphate–cit-
rate buffer with 150 mM NaCl at three pH values: 3, 5, and 8. After
dialysis, it was found that there was a signiﬁcant amount of insol-
uble protein aggregates in the pH 3 sample, as assessed visually
and by size exclusion chromatography (data not shown). There-
fore, the sample was centrifuged at 194,000g for 1 h using an
sw55Ti rotor in a Beckman Optima LE-80k ultracentrifuge. The
resulting supernatant was used for the experiments. Protein con-
centration of samples at all three pHs was adjusted to 37 mg/ml.
For comparison of effects of pH on structure and HSA size, DLS data
and Raman spectra were ﬁrst obtained at 20 C. Then, data were
acquired at an interval of 1 C during heating from 20 to 90 C.
Effects of oxidation with H2O2 on HSA structure, aggregation, and
thermal stability
HSA (in 20 mM sodium phosphate–citrate buffer at pH 7 with
150 mM NaCl) at a protein concentration of approximately
46 mg/ml was incubated at 37 C with and without 3% H2O2 (v/v)
for 5 days. After incubation, the HSA samples that had been incu-
bated with and without H2O2 were dialyzed at 4 C against
20 mM sodium phosphate–citrate buffer (pH 7 with 150 mMNaCl),
with three changes of the external solution, the volume of which
exceeded sample volume by 1000-fold. Protein concentration
was adjusted to 18 mg/ml. For comparison of effects of oxidation
on HSA structure and size, DLS data and Raman spectra for oxi-
dized and control samples were ﬁrst obtained at 20 C.
The oxidized and control HSA samples were also analyzed by
SEC to quantify levels of soluble aggregates. An Agilent 1100 col-
umn (Santa Clara, CA, USA) and a Tosoh TSK G3000SWXL column
(San Francisco, CA, USA) (7.8  300 mm2) were used. The mobile
phase consisted of 100 mM sodium phosphate (pH 7), 100 mM
sodium sulfate, and 0.05% (w/v) NaN3, and the ﬂow rate was
1 ml/min.
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protein aggregates were removed from the samples by centrifuga-
tion at 194,000g for 3 h with an sw55Ti rotor in a Beckman Optima
LE-80k ultracentrifuge. The control sample, which had not been
treated with H2O2, was also processed by ultracentrifugation. The
protein concentrations in the supernatants of both samples were
adjusted to 18 mg/ml. Thermal stability was studied with Raman
spectroscopy and DLS during heating from 20 to 90 C with a heat-
ing interval of 1 C.
Thermal stability of IVIG
To remove any aggregates and particles, IVIG from the product
vial was centrifuged at 194,000g for 3 h with an sw55Ti rotor in a
Beckman Optima LE-80k ultracentrifuge. The resulting supernatant
was removed, and the protein was diluted to 51 mg/ml with the
IVIG product formulation buffer (0.25 M glycine, pH 5). DLS data
and Raman spectra were acquired at an interval of 1 C during
heating from 20 to 90 C.
Results and discussion
Initial thermal stability study of HSA
The initial study investigated structural transitions and aggre-
gation during heating of a high-concentration (39 mg/ml) solution
of HSA. Aggregation was monitored with DLS, and structural tran-
sitions were assessed based on temperature-dependent changes in
the Raman spectra for the protein. Furthermore, as a relative mea-
sure of protein aggregation propensity and thermal stability, tem-
peratures at which there were transitions in measured parameters
by either method were calculated and compared.
There are several structural elements in proteins for which
bands in the Raman spectrum can be assigned, and such assign-
ments have been made in the literature for HSA [13,15,24–26].
For the HSA spectrum shown in Fig. 2, the peak from around
1650 to 1680 cm1 was assigned to amide I, which results from
the protein backbone’s C@O stretching coupled with minor contri-
butions from C–N stretching and N–H in-plane bending [18,26].
The amide I band is sensitive to alterations in a protein’s secondaryFig.2. Effects of heating on Raman spectra of HSA and selected spectral elements.
HSA was studied at pH 7 and a concentration of 39 mg/ml. The main ﬁgure shows
Raman spectra with normalized intensities acquired at 20, 65, 70, and 80 C. The
vertical dashed lines were drawn to highlight the change of characteristic Raman
bands along with the change of temperature. The upper left inset shows the
intensity of the skeleton vibration at approximately 941 cm1 (red rectangles), the
amide III band at 1245 cm1 (green triangles), and the intensity ratio of Tyr at 850
and 830 cm1 (blue circles) as a function of temperature. The upper right inset has
the second derivative of the amide I region acquired at various temperatures during
heating. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)structure [13,27]. At 20 C, the peak position of the amide I band
was located at 1653 cm1, and this band was assigned to a-helix
[26,28]. As temperature increased to 65 C, no signiﬁcant peak
shifting was observed for the amide I band. However, by the time
the temperature reached 70 C, there was peak broadening and a
shoulder appeared at 1670 cm1 (Fig. 2). At 80 C, the peak shifted
more toward 1670 cm1. The amide I peak shifting and broadening
during heating were consistent with the gradual loss of a-helix
structure and concomitant formation of b-sheet and random coil
[24,25,29].
To more clearly resolve the component Raman spectral bands
within the amide I region and temperature-dependent changes,
the second derivative for this region was calculated (Fig. 2, upper
right inset). As temperature increased, there was a clear loss of
peak intensity at 1653 cm1 that was accompanied by an increase
of peak intensity at 1670 cm1. Thus, as noted above, during heat-
ing of HSA, there is a loss of native a-helix and formation of non-
native b-sheet and random coil [24,25,29]. An isosbestic point
between the two peaks further conﬁrmed the direct transition of
native to non-native secondary structural elements in HSA during
heating (Fig. 2, upper right inset).
The amide III band at around 1245 cm1, another indicator for
secondary structure, is attributed to the in-plane bending of N–H
and stretching of C–N [13,25]. The increased intensity of the
1245-cm1 peak with temperature also can be assigned to the for-
mation of b-sheet structure during heating (Fig. 2, upper left inset).
The Raman band at 941 cm1 (Fig. 2) is usually referred to as
the amide skeleton band and results from the N–Ca–C stretching
of the peptide backbone [13,27]. For the Raman spectrum of HSA,
this band is a marker of a-helix structure [27]. The reduction in
intensity at 941 cm1 during heating further conﬁrms the loss of
native a-helix structure of HSA.
By monitoring the Fermi doublets at 850 and 830 cm1, infor-
mation was obtained about heating-induced changes in HSA’s ter-
tiary structure. These spectral features are assigned to the
vibrational frequencies of tyrosine, and a change in the intensity
ratio of the two peaks (I850/I830) reﬂects a change in the microenvi-
ronment around tyrosine [13,17]. A higher value indicates that the
residue is either in a hydrophobic environment or in a polar envi-
ronment but only moderately hydrogen bonded. In contrast, the
value becomes lower if the phenolic hydroxyl oxygen is ionized
or becomes a strong hydrogen bond donor [15,17]. Therefore, the
decrease of I850/I830 for HSA from 1.4 to 0.8 during heating
(Fig. 2) suggests that there was a tertiary structural change in
which Tyr residues as donors were more strongly hydrogen
bonded to a negative-charge receptor such as a carboxylate ion
[15,17].
As an example of comparisons that can be made between the
heating-induced changes in markers of secondary and tertiary
structures, the intensity of the amide skeleton band at 941 cm1
and the values for I850/I830 were plotted versus temperature
(Fig. 2, upper left inset). For secondary structure, there was not a
substantial change until the temperature reached approximately
67 C, above which there was a relative steep drop in band inten-
sity. Conversely, the tertiary structure as reﬂected in the values
for I850/I830 began to be gradually altered as temperature increased
above approximately 35 C and then underwent a more dramatic
change starting at approximately 67 C. Thus, prior to secondary
structural transitions, heating leads to perturbation of tertiary
structure, and then at higher temperatures it appears that second-
ary structural changes result in further tertiary structural
alterations.
To assess quantitatively heating-induced changes in HSA sec-
ondary structure, the Raman spectra were analyzed with two dif-
ferent approaches. In the ﬁrst, from the second derivative spectra
in the amide I region, the intensities were determined for the a-
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values were plotted versus temperature, and curves were ﬁt to
the resulting plots (see Materials and Methods for details). Based
on the ﬁt curves, Tonset and Tm values were determined (Fig. 3A).
For the a-helix band, these were 67.0 ± 0.2 and 68.1 ± 0.4 C,
respectively. For the b-sheet band, the corresponding values were
66.0 ± 0.2 and 69.5 ± 0.2 C. Therefore, the thermal transitions for
loss of a-helix band intensity and the gain in b-sheet occurred at
essentially the same temperatures. This observation was consis-
tent with the conclusion that during heating of HSA there was a
direct conversion of a-helix to b-sheet.
In the second approach, a database provided by Malvern con-
tained Raman spectra of 18 proteins with known secondary struc-
ture contents. In addition, a partial least squares (PLS) analysis
routine for this spectral database was developed by Malvern. Based
on PLS analysis of the HSA spectrum, at 20 C the protein contained
68% a-helix and 0% b-sheet, which matches well with values
obtained by X-ray crystallography [30]. The percentages of a-helix
and b-sheet were then plotted versus temperature, and curves
were ﬁt to the plots using a sigmoidal model as described in Mate-
rials and Methods (Fig. 3A). Based on the ﬁt curves, Tonset and Tm
values were determined. For the a-helix content, these were
67.0 ± 0.1 and 70.2 ± 0.2 C, respectively. For the b-sheet content,
the corresponding values were 67.0 ± 0.2 and 70.3 ± 0.2 C.
Therefore, with both methods of determining thermal transition
temperatures, consistent values were obtained and the results doc-
umented that loss of a-helix in HSA during heating was concomi-
tant with an increase in b-sheet content.Fig.3. (A) Two ways to characterize the alteration of secondary structure occurring durin
calculated from the Raman spectra using a PLS model as described in Materials and Meth
in the second-derivative (2D in the legend) spectra were plotted. The solid lines shown ar
measured intensity distributions for HSA obtained during heating shown for selected
temperature.The underlying cause of this structural conversion was revealed
by examining the DLS data (Fig. 3B) for HSA that were obtained
during the same heating experiments as the Raman spectra. At
20 C, the z-averaged hydrodynamic diameter was 7.3 nm, which
is consistent with values for HSA in the literature [31]. At 20 C,
the intensity distribution was monodispersed and it remained this
way during heating until 63 C, at which point a peak with approx-
imately 200 nm size was observed, indicating the onset of heating-
induced of aggregation (Fig. 3B). At 65 and 70 C a peak for inter-
mediate-sized aggregates was observed, and at 70 C there was
an additional peak centered around 400 nm. At temperatures
higher than 74 C, the sample was visually observed to be grossly
precipitated and the ﬁts to the correlation function data were rel-
atively poor. Thus, size distributions could not be determined
above this temperature.
The z-average values for HSA size were plotted as a function of
temperature. As heating progressed to 62 C there was no observa-
ble change, but above this temperature there was a large increase.
A curve was ﬁt to the plot of values versus temperature, and the
Tagg value was determined (Fig. 3C). The Tagg value was lower than
Tonset for secondary structural changes (63.5 vs. 66 C). The dis-
crepancy is probably due to the fact that DLS is very sensitive to
large particles because the scattering intensity is proportional to
the sixth power of the particle diameter. Thus, the size measured
will be skewed to a larger value when even a minute amount of
large aggregates is present, that is, less than 1% in mass. With
Raman spectroscopy, like all of the other spectroscopic techniques,
the spectra represent the average structure of all sub-populationsg heating of HSA. In the ﬁrst approach, the percentages of a-helix and b-sheet were
ods. In the second approach, the relative intensities of the a-helix and b-sheet bands
e those resulting from sigmoidal ﬁtting of the data points used for each plot. (B) DLS
temperatures. (C) The z-averaged hydrodynamic size of HSA (39 mg/ml) versus
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perturbed protein molecules. Thus, even though conversion of a
few percentage points of HSA molecules into large aggregates
would have a large effect on DLS z-average values, the correspond-
ing Raman spectra would not be detectably altered from those
observed for the fully native protein.
Overall, the data from Raman spectroscopy and DLS showed
that during heating of HSA the ﬁrst detectable change was pertur-
bation of tertiary structure. As the temperature increased further,
the protein aggregated and it was the process of aggregation that
caused the loss of native a-helix and the concomitant increase in
non-native intermolecular b-sheet. This conclusion is consistent
with the commonly found phenomenon that during heating partial
unfolding of native structure results in protein aggregation, which
in turn is associated with a loss of native secondary structure and
formation of intermolecular b-sheet [18,32–35]. These results
show the importance of having an independent, but concomitant
measure of protein aggregation when studying heating-induced
structural transitions of proteins.
Effects of protein concentration and data acquisition interval on HSA
thermal stability
To assess the effect of protein concentration on HSA thermal
stability, samples of 10, 15, 20, and 39 mg/ml were analyzed at
pH 7. At 20 C, there were no detectable differences between the
Raman spectra of HSA at the different concentrations (see Fig. S1
in online Supplementary material). However, the spectral quality
increased in direct proportion to the protein concentration. During
heating, the peak centers of amide I spectra for HSA at all concen-
trations studied increased from around 1653 to 1661 cm1. The
Tonset and Tm values calculated from the sigmoidal ﬁtting of the
temperature-dependent position of amide I are shown in Table 1.
Based on both values, under the conditions of our experiments,
protein concentration did not affect the stability of HSA during
heating (Table 1).
The Tagg values obtained from the temperature-dependent z-
averaged hydrodynamic size also did not vary with protein concen-
tration (Table 1). However, the greater the protein concentration
was, the larger the z-averaged size was for the sample after theTable 1
Onset and midpoint temperatures for structural changes and aggregation onset
during heating.
Experimental parameter tested Tonset (C) Tm (C) Tagg (C)
HSA concentration
10 mg/ml 65.8 ± 0.9 71.0 ± 1.4 65.0 ± 0.5
15 mg/ml 65.4 ± 0.6 69.5 ± 0.4 64.8 ± 0.1
20 mg/ml 66.0 ± 0.0 70.4 ± 0.7 64.8 ± 0.6
39 mg/ml 66.7 ± 0.6 70.7 ± 0.7 64.4 ± 0.6
Heating increment for HSA solution
0.5 C/step 65.2 ± 0.8 70.1 ± 0.4 62.6 ± 0.2
1 C/step 65.0 ± 0.0 69.9 ± 0.1 63.3 ± 0.3
2 C/step 65.2 ± 0.2 70.0 ± 0.2 64.1 ± 0.2
5 C/step 65.3 ± 0.2 70.4 ± 0.3 64.0 ± 1.7
pH of HSA solution
pH 3 49.3 ± 0.6 58.9 ± 0.4 45.7 ± 0.9
pH 5 63.3 ± 0.6 66.5 ± 0.3 54.8 ± 0.5
pH 8 65.0 ± 0.0 69.4 ± 0.2 61.8 ± 0.3
H2O2-induced HSA oxidation
Untreated HSA 66.0 ± 1.2 70.2 ± 0.8 57.0 ± 1.9
H2O2-treated HSA 58.0 ± 1.2 68.0 ± 0.5 64.4 ± 0.1
IVIG aromatic side chain
Tyr 830 cm1 61.0 ± 1.4 68.0 ± 1.7 N/D
Tyr 850 cm1 60.0 ± 0.8 66.0 ± 1.7 N/D
Trp 1550 cm1 59.0 ± 2.8 69.0 ± 2.5 N/D
Trp 1340/1360 cm1 62.7 ± 1.2 68.1 ± 0.9 N/Daggregation onset (Fig. 4B, inset). More speciﬁcally, at 67 C, the
HSA sample at 10 mg/ml showed two unresolved peaks with z-
averaged size of 18 nm, whereas for the sample at 39 mg/ml two
peaks at 10 and 100 nm were well resolved with z-averaged size
of 55 nm.
The heating step is an operational parameter that can poten-
tially affect thermal stability evaluations for proteins. To gain
insight into the effects of heating step interval on protein thermal
stability, HSA at 41 mg/ml was evaluated with a heating interval of
0.5, 1, 2, or 5 C. There were no discernible differences in the heat-
ing-induced shifts in the amide I band (Fig. 5A) or in the calculated
values for Tonset and Tm (Table 1). Temperature-dependent DLS data
(Fig. 5B and Table 1) showed that the Tagg values also were not
affected by heating interval. But the sizes of aggregates obtained
were slightly larger for samples studied in experiments with the
smaller heating intervals than for those observed with larger inter-
vals (Fig. 5B, inset). This effect was probably because the sample
was exposed to higher temperatures for a longer time during the
experiments with the smaller data acquisition intervals.
Isothermal incubation of HSA
The kinetics of structural alterations and aggregation for HSA
were evaluated during isothermal incubation at 60, 63, and 65 C,
which were near the onset temperatures for the thermal transi-
tions observed during heating experiments. In Fig. 6A, the Raman
amide I band position was plotted against the duration of incuba-
tion. At the 20 C starting point, the values were 1654.3, 1654.3,
and 1654.7 cm1 for HSA incubated at 60, 63, and 65 C, respec-
tively. The shift to higher wave numbers was faster and to a greater
degree at 65 C than that observed at 63 C; there was almost no
change for the amide I peak center at 60 C. After 200 min of incu-
bation, the amide I peak was centered at 1654.5, 1655.4, and
1656.8 cm1 for 60, 63, and 65 C, respectively. As a direct reﬂec-
tion of protein secondary structure, the amide I peak shifting indi-
cates the structural perturbation rate and extent were both
positively correlated with the temperature. As expected, structure
perturbation also positively correlated with the increase of z-aver-
aged size (Fig. 6B). With starting points of 7.9, 8.4, and 9.9 nm for
HSA incubated at 60, 63, and 65 C, respectively, the z-averaged
size increased to 9.9, 34, and 116.5 nm, respectively, after
200 min of isothermal incubation. The protein aggregated the fast-
est and to the greatest extent at 65 C.
Notably for the sample incubated at 63 C, the magnitude of the
increase in z-averaged size was substantially greater than that of
the increase in amide I peak position. As discussed above, conver-
sion of a small fraction of the protein population into larger aggre-
gates could result in a substantial increase in the z-average value
because of the great increase in light scattering with size. In con-
trast, even if HSA molecules in the aggregates had greatly per-
turbed secondary structure, with a relatively small fraction
converted into aggregates, the impact on Raman spectra would
be minor. This is because under these conditions the overall aver-
age secondary structure of all protein molecules in the sample
would be only slightly altered.
Effects of pH on HSA structure and thermal stability
The effects of pH on the structure and thermal stability of HSA
have been characterized by various techniques such as CD spec-
troscopy, differential scanning calorimetry (DSC), and ﬂuorescence
spectroscopy, but the earlier studies were performed at relatively
low protein concentrations [21,36–39]. Here, we used the
Raman–DLS system to study effects of pH on the structure and
thermal stability of HSA at the relatively high concentration of
37 mg/ml. At 20 C, as compared with the Raman spectra for the
Fig.4. (A) Effect of protein concentration on the Raman spectra amide I peak centers during heating of HSA. The protein was studied (pH 7) at protein concentrations of 10, 15,
20, and 39 mg/ml. (B) Effect of protein concentration on the z-averaged hydrodynamic size of HSA during heating. The inset shows the intensity distribution of sizes measured
by DLS at 67 C. Error bars denote standard deviations for values obtained for independent samples (nP 2).
Fig.5. (A) Effect of heating step size on the Raman spectra amide I peak centers during heating of HSA (41 mg/ml). (B) Effect of heating step size on the z-averaged
hydrodynamic size of HSA during heating. The inset shows the intensity distribution of sizes measured by DLS at 65 C. Error bars denote standard deviations for values
obtained for three independent samples.
Fig.6. Effect of temperature on Raman spectra amide I peak centers (A) and z-averaged hydrodynamic size (B) during isothermal incubation of HSA (31 mg/ml HSA at pH 7).
Error bars denote standard deviations for values obtained for three independent samples. In some cases, error bars are not visible because standard deviations were smaller
than the symbols.
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showed a slight intensity loss at 1654.5 cm1 and gain at
1670 cm1 (Fig. 7A). This change is attributed to a reduction in
a-helix content of HSA at pH 3 [21]. There were also decreases in
the intensities at 941 cm1 and at 1320 cm1, which furtherconﬁrmed the helical structure decrement (see Fig. S3 in Supple-
mentary material). It has previously been shown that HSA has a
compact conformation between pH 4.3 and 10 and converts to a
more open structure with reduced helix content—in a process
referred to as ‘‘acid expansion’’—below pH 4.3 [21,36,37]. Consis-
Fig.7. Effect of pH on HSA (37 mg/ml) structure and size. (A) Second derivative of amide I region of the Raman spectra acquired at 20 C. (B) a-Helix percentage during
heating. Helix content was calculated from the Raman spectra as described in Materials and Methods. (C) The z-averaged size during heating. (D) The z-averaged size and
Raman spectra tertiary structure marker, Tyr 850 cm1 band position, at pHs 3, 5, and 8. The ﬁrst 20 data points from 20 to 39 C during heating were chosen. In panels B and
C, error bars denote standard deviations for values obtained for three independent samples.
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size of HSA was approximately 7, 8, and 9 nm at pHs 8, 5, and 3,
respectively.
For the thermal stability study, Raman spectra were collected
for HSA samples at each pH from 20 to 90 C (see Fig. S4 in Supple-
mentary material). For samples at pHs 5 and 8, HSA started with
68% helix content and this value did not change substantially until
65 C (Fig. 7B). Then, the content dropped relatively steeply with
temperature at pH 5 compared with the temperature-induced
structural change in HSA observed at pH 8. The HSA sample at
pH 3 started with slightly lower helix content (66%) and went
through a broader and more gradual temperature-induced transi-
tion but with an earlier onset temperature. However, by the point
the samples reached 90 C, HSA helix contents were similar to val-
ues of 35, 32, and 35% at pHs 3, 5, and 8, respectively.
The Tonset and Tm of secondary structural transitions were deter-
mined, and the values of both followed the trend of pH 3 < pH
5 < pH 8 (Table 1). These results demonstrated that HSA thermal
stability is substantially reduced at pH 3.
During heating at pH 3, the z-averaged size of HSA started at
9 nm (20 C) and increased gradually with temperature (Fig. 7C).
Aggregation was ﬁrst observed at 45.7 ± 0.9 C, as evidenced by
the increase of the z-averaged size to approximately 11 nm. By
the time the sample reached 90 C, the z-averaged size was approx-
imately 70 nm. Macroscopically at this point, the sample was visu-
ally a transparent diffuse gel. For HSA at pH 5, there was a sharp
transition to larger z-average size starting at 54.8 ± 0.5 C, and after
heating the aggregated sample had formed a white precipitate. At
pH 8 the transition occurred at 61.8 ± 0.3 C, and during heatingthe sample formed an opaque gel. For HSA at both pHs, the last size
data with correlation coefﬁcient higher than 0.85 indicated a z-
averaged size of 287.7 nm for pH 5 at 61 C and 198.2 nm for pH
8 at 74 C.
The smaller size increase for HSA at pH 3 during heating could
be due to highly charged protein molecules and charge–charge
repulsion between protein molecules and/or nanoparticles formed
during heating. Previously, it has been observed that HSA at pH 2
aggregated less than the protein at pH 7 during heating from 25
to 90 C [40]. Thus, even though HSA has a perturbed conformation
at low pHs, the high positive charge of the molecules limits the
magnitude of aggregation during heating; conformational stability
of HSA is reduced, but colloidal stability is increased.
Finally, in Fig. 7D, for each pH studied the z-averaged size for
HSA is plotted against the Tyr 850 cm1 peak center at low temper-
atures (20–39 C) where no signiﬁcant aggregation or denaturation
had taken place. It is clear from this plot that HSA at pH 3 has a per-
turbed tertiary structure and expanded monomer size compared
with HSA at pHs 5 and 8. Although the secondary structure differ-
ences were small among pHs 3, 5, and 8 (Fig. 7A), the combination
of size and tertiary structure marker Tyr 850 cm1 could be used to
capture and amplify the small differences in the protein’s
structure.
Effects of oxidation with H2O2 on HSA structure, aggregation, and
thermal stability
Oxidation of therapeutic proteins can occur during production
in cell cultures due to dissolved oxygen and during downstream
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due to light exposure and/or impurities in excipients and their deg-
radation [41]. Furthermore, often the oxidation of a therapeutic
protein causes decreased conformational stability and increased
aggregation [41–46]. To evaluate the effects of oxidation on HSA
structure and aggregation, we ﬁrst employed an accelerated degra-
dation approach in which experimental samples were exposed to
3% (v/v) H2O2 at 37 C over 5 days and then analyzed for aggrega-
tion by DLS and structural alterations by Raman spectroscopy. SEC
was also used to characterize and quantify protein aggregates.
Control samples that were incubated at 37 C without H2O2 were
similarly analyzed. For the control HSA sample, even after the 5-
day incubation, no signiﬁcant aggregation occurred relative to that
found in the starting material, as assessed by both DLS and SEC (see
Fig. S5 in Supplementary material). However, for H2O2-treated
HSA, signiﬁcant aggregation was observed (Fig. 8). DLS intensity
percentage results for the control HSA sample had a monodi-
spersed peak with a center close to 7 nm. In contrast, for the
H2O2-treated HSA sample, there was an additional prominent peak
at 30 nm and the z-average size increased greatly (Fig. 8A and C).
When DLS results of the H2O2-treated HSA were converted to vol-
ume percentage for the main peak, there was a tailing in the
greater than 10-nm size range, indicating that a fraction of the pro-
tein population had aggregated (Fig. 8B). For the control HSA sam-
ple, the majority of the protein was monomeric with a minute
fraction of high-molecular-weight species. For the H2O2-treated
sample, as assessed by SEC analysis, there was a substantial
decrease in the amount of monomeric HSA and a concomitant
increase in high-molecular-weight species (Fig. 8D). Thus,Fig.8. Effects of incubation at 37 C, with and without 3% H2O2 (v/v), on HSA (18 mg/ml)
hydrodynamic size. (D) SEC chromatograms. In panels A, B, and C, error bars denote staoxidative stress of HSA under accelerated degradation conditions
fostered aggregation of the protein, and DLS results plotted as
intensity percentage provided a sensitive means by which to detect
the aggregates.
In the Raman spectra of the H2O2-treated HSA, there was only
slight peak shifting and broadening in the amide I region (see
Fig. S6 in Supplementary material), which suggests that secondary
structure was not signiﬁcantly altered. Similarly, Raman spectra in
the regions of amide I, amide III, and the backbone skeleton bands
indicated that the treated HSA did not have observable alterations
in secondary structure (data not shown). A recent study also eval-
uated the effects of H2O2 on the structure and aggregation of HSA
employing infrared spectroscopy, far-UV CD spectroscopy, and
light scattering. It was also found that the secondary structure of
HSA was not affected signiﬁcantly by H2O2 treatment [47].
However, differences in the Raman spectra for control and
H2O2-treated HSA were observed in the 800- to 1300-cm1 region
(Fig. 9A). In both the raw spectrum for H2O2-treated HSA and the
difference spectrum, a new peak at around 1045 cm1 was appar-
ent. This peak has been assigned to SO2 stretching and was proba-
bly due to methionine and/or cystine oxidation [47–50]. However,
the oxidation stress employed in our experiment was not as harsh
as that described in earlier studies [48,49] where the peracid oxi-
dation of disulﬁde bridges of the cystine was induced by much
higher concentrations of H2O2. Therefore, in the spectrum for
H2O2-treated HSA from our studies, the SO2 stretching band was
more likely due to methionine oxidation, which does not require
as harsh treatment conditions as those required for cystine oxida-
tion [47,48].size. (A) DLS intensity distribution. (B) DLS volume distribution. (C) DLS z-averaged
ndard deviations for values obtained for three independent incubated samples.
Fig.9. (A) Raman spectra acquired at 20 C (800–1300 cm1) of 18 mg/ml HSA with and without H2O2 treatment. The scaled difference spectrum is also shown. The SO2
stretching reﬂected by the increase of intensity at 1045 cm1 is labeled in the ﬁgures. The spectra are the averages of triplicate samples. (B) Shifting of amide I peak centers of
HSA with and without H2O2 treatment during thermal ramping. (C) The z-averaged hydrodynamic size of HSA with and without H2O2 treatment during thermal ramping.
Error bars denote standard deviations of three independent samples.
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the aggregates formed during the 5-day incubation were removed
by preparative ultracentrifugation. The control sample was also
processed by ultracentrifugation. The protein concentrations in
the supernatants of both samples were adjusted to 18 mg/ml,
and thermal stability was studied with Raman spectroscopy and
DLS (Fig. 9B and C). As observed in our earlier experiment
(Fig. 4A), the amide I peak position for control untreated HSA
started from 1654 cm1 at 20 C and shifted up to 1662 cm1 at
90 C. With the H2O2-treated sample, the peak center was approx-
imately 1655 cm1 at 20 C, and the ﬁnal peak position was
1662 cm1 at 90 C. With H2O2-treated HSA, there was a gradual
transition during heating rather than the sharp one noted for tem-
perature-dependent peak position for the untreated HSA sample.
H2O2-treated samples had lower Tonset and Tm values than the
untreated protein (Table 1), indicating that oxidation reduced ther-
mal stability. Similarly, by DLS, H2O2-treated HSA showed a lower
Tagg value as compared with that for untreated HSA (Table 1).
It should be noted that, even after ultracentrifugation to remove
the aggregates of HSA formed during H2O2 treatment, the hydrody-
namic diameter determined from DLS was approximately 14 nm
compared with 7 nm for the control sample of HSA. The presenceof residual aggregates, as well as oxidized HSA molecules, in the
treated sample might have contributed to the greater hydrody-
namic diameter and lower thermal stability. In an earlier study
[47], however, based on Rayleigh light scattering intensity, oxi-
dized HSA had a lower aggregation propensity during heating than
untreated HSA. The discrepancy between our results and those
from the earlier study might be because in our experiment the
HSA was stressed with H2O2 longer and at higher temperature
(37 C for 5 days vs. 25 C for 1 day). In addition, the protein con-
centration in our experiment was 46 mg/ml versus 2 mg/ml in
the earlier study. These differences in results between the two
studies further illustrate that one cannot assume that similar
effects will be observed during heating studies unless all condi-
tions are exactly matched between experiments.
Thermal stability of IVIG
Monoclonal antibodies have become one of the most important
categories of therapeutic proteins, and evaluation of thermal
stability is crucial for research and development of antibody
therapeutic products [51,52]. Because these products are often
used at relatively high doses when delivered by subcutaneous
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50 to 100 mg/ml or maybe even higher. And for thermal stability
assessment, it is important to study protein samples at the high
concentrations used for the actual dosage form.
To mimic such studies, we examined the thermal stability of an
ultracentrifuged IVIG sample at 51 mg/ml by Raman spectroscopy
and DLS. The protein solution was prepared in the commercial
product formulation of 250 mM glycine buffer at pH 5. The Raman
spectra at 20, 60, and 90 C were selected for initial comparison
(Fig. 10). In contrast to results with HSA, which has mostly native
a-helix structure, there were minimal temperature-induced shifts
in the amide I peak position for the spectra of IVIG at 20 to 90 C
(Figs. 10 and 11A). For the IVIG sample, the amide I band was
slightly broadened and the center of the amide I peak shifted
slightly from 1668.4 to 1669.8 cm1. PLS analysis of overall sec-
ondary structure of IVIG at 90 C did show an approximately 5%
increase in b-sheet structure. This was far lower than the 40%
increase observed for HSA. Antibodies have mostly b-sheet native
secondary structure. Therefore, formation of intermolecular b-
sheet during protein aggregation was not expected to result in as
much increase in overall b-sheet content measured with Raman
spectroscopy as that observed with HSA. In addition, with Raman
spectroscopy, we were not able to distinguish intermolecular b-
sheet in aggregated IVIG from intramolecular b-sheet in the native
protein.
Considering the limited resolution with individual spectra for
detecting the secondary structural transition of IVIG during heat-
ing, we determined difference spectra by subtracting the spectrum
obtained at 20 C from those for the protein at different tempera-
tures during heating (Fig. 11B). With this approach we were able
to resolve increased intensities in bands at 1668 and 1686 cm1
with increased temperature (Fig. 11C). Difference spectra provided
a sensitive means by which to detect the small increases in b-sheet
content in the IVIG sample during heating studies and might be
particularly useful for studying mAb therapeutic products.
Assessment of tertiary structure during heating also improved
the resolution of structural changes detected with Raman spectros-
copy. During heating of IVIG, the Raman spectra showed substan-
tial peak shifts for the tyrosine Fermi doublet at 850 and
830 cm1 and tryptophan at 1550 cm1 (Fig. 10, inset). There was
an approximately 2 cm1 reduction in peak positions for the Tyr
850 and 830 cm1 peaks. The Trp 1550 cm1 peak downshifted atFig.10. Comprehensive analysis of Raman spectra of 51 mg/ml IVIG during thermal
ramping from 20 to 90 C. Spectra at 20, 60, and 90 C are selectively shown for
comparison. The vertical dashed lines were drawn to highlight the changes of
characteristic Raman bands along with the change of temperature. The peak
shifting of Tyr 850 and 830 cm1 is shown in the upper left inset, and the peak
shifting of Trp 1550 cm1 is shown in the upper right inset. Error bars denote
standard deviations of three independent samples.around 3 cm1. Those peak shifts were caused by changes of the
local environment of Tyr and Trp, consistent with tertiary struc-
tural alterations of IVIG during heating [13]. The Tonset and Tm val-
ues were determined for Tyr 830 cm1, Tyr 850 cm1, and Trp
1550 cm1, as shown in Table 1. In addition, the intensity ratio of
the Fermi doublet of Trp at 1360 and 1340 cm1, another tertiary
structure marker for proteins [13], went from 0.3 to 0.05 (data
not shown), with the Tonset at 62.7 ± 1.2 C and Tm at 68.1 ± 0.9 C
(Table 1).
In an earlier study, second-derivative UV spectra and intrinsic
ﬂuorescence spectroscopy of mAb samples also indicated that
Trp had increased solvent exposure with increasing temperature
[53]. As shown in our work and the earlier study, changes in ter-
tiary structure could be especially valuable to understand mAb
structure and thermal stability under circumstances where mini-
mal secondary structure changes occur [54].
Based on the concomitant DLS analysis in our study of IVIG,
aggregation was initiated at approximately 56 C and proceeded
further as the temperature increased to form large assemblies of
more than 100 nm at 90 C (Fig. 12A and B). The initial apparent
hydrodynamic diameter was 3.5 nm at 20 C as compared with
typical mAb size of approximately 10 nm [55], which is most likely
due to the solution conditions employed and the relatively high
concentration of IVIG in the sample. The macromolecule concen-
tration effect on molecular diffusion has been developed as [56]
Dm ¼ D0½1þ KDC þ K2C2 þ . . .; ð2Þ
where Dm is the mutual diffusion coefﬁcient or the apparent diffu-
sion coefﬁcient, Do is the value of Dm at inﬁnite dilution, KD is the
ﬁrst-order interaction parameter, K2 is the second-order interaction
parameter, and C is the protein concentration. At relatively low pro-
tein concentration, the higher order concentration effect, K2, and
above are negligible, and the ﬁrst-order interaction parameter, KD,
could be measured by the correlation between diffusion coefﬁcient
and protein concentration to reﬂect the extent of intermolecular
interaction [57]. For example, the apparent diffusion coefﬁcient of
a mAb (pI = 8.5) measured with DLS increased almost linearly with
an increase in protein concentration in the range of 2 to 12 mg/ml at
pHs 4 and 6 [58]. At pHs 4 and 6, the net positive charge on the mAb
molecule dominates intermolecular interactions, and the repulsive
interaction causes the positive correlation of Dm to protein concen-
tration (or positive KD) [58]. At higher protein concentration, not
only electrostatic interactions but also factors such as van der Waals
interactions and excluded volume effects should be considered [59].
In our study, with the pI of immunoglobulin G (IgG) molecules in
IVIG ranging from approximately pH 4.7 to 7.5 [22], the majority
of the IgG population should be positively charged at pH 5. There-
fore, repulsive interactions between the positively charged mole-
cules and an increased diffusion coefﬁcient is expected with
increasing protein concentration. In fact, an increase in the apparent
diffusion coefﬁcient was seen when the IVIG protein concentration
was increased from 1 to 50 mg/ml (data not shown), and the appar-
ent size of IVIG decreased from 9 to 3.4 nm. However, this underes-
timation of molecular size should not affect aggregation onset point
determinations because these values depend on the relative size
change rather than the absolute size.
Usually, high-concentration mAb formulations pose challenges
for analytical characterization and formulation development.
Attemptshavebeenmade to obtain analytical data of highly concen-
trated solutions ofmAbs, either solely by infrared spectroscopy [60]
or with infrared spectroscopy combined with a series of slightly
modiﬁed biophysical methods [53,61]. For the former, the thermal
stability of bovine IgG was tested up to 200 mg/ml at varied pH val-
ues. For the latter, ﬂuorescence, UV, CD, and infrared spectroscopies
and DSC were combined to test the effects of pH on the thermal
Fig.11. (A) Amide I region in the Raman spectra for IVIG acquired at 20 and 90 C during heating. (B) Difference spectra in the amide I region obtained by subtracting the
Raman spectrum at 20 C from those acquired during heating at the designated temperatures. (C) Intensities of bands at 1668 and 1686 cm1 in the difference spectra as a
function of temperature.
Fig.12. (A) The z-averaged hydrodynamic size of IVIG during heating. (B) DLS intensity distributions of IVIG at 20, 40, 50, 60, 70, and 80 C. In panel A, error bars denote
standard deviations of values obtained for three independent samples.
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ml. Interestingly, at pH 6, the bovine IgGwas found to have increas-
ing Tm values from 71 to 73 C when the protein concentration
increased from 25 to 100 mg/ml, but the value decreased slightly
at 200 mg/ml. However, for the study of the two mAbs, spectro-
scopic techniques probing tertiary structure demonstrated a
decrease in the apparent thermal melting temperature of approxi-
mately 5 to 20 C with increasing protein concentration. In these
two studies, the apparent melting temperature decrement was
attributed to increased aggregation at higher protein concentration.
However, no direct sizemeasurements were performed. Converselyin another recent study, only light scattering was applied to charac-
terize protein aggregation at concentration up to 190 mg/ml, but no
structure information was supplied [61]. In contrast, with the com-
bined DLS–Raman system, both protein conformational and aggre-
gation can be studied at the same time.
Conclusions
The combination of Raman spectroscopy and DLS offers unique
advantages such as low sample volume requirement, easy back-
ground subtraction, compatibility with high protein concentration,
Raman–DLS system to characterize therapeutic proteins / C. Zhou et al. / Anal. Biochem. 472 (2015) 7–20 19and simultaneous analysis for both size and conformation, includ-
ing protein secondary and tertiary structure information. The
robustness of a combined Raman–DLS system for protein thermal
stability evaluations has been documented by the current study,
and further applications of this system for other protein systems
will be forthcoming.
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